Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company, focuses on the development and commercialization therapeutic products for the treatment for cardiovascular diseases. Its product development program areas include lipid science and therapeutic benefits of polyunsaturated fatty acids. Vascepa[(R)] (icosapent ethyl), Amarin's first FDA approved product, is a patented, ultra pure omega-3 fatty acid product comprising not less than 96% EPA and is available by prescription. AMRN closed up 9cents per share on Friday (August 23, 2013) on over 3.9Million shares traded.
Microsoft Corp. (NASDAQ: MSFT) is expected remain in the spotlight on Monday as investors assess whether to extend the Ballmer bounce -- the best one-day gain in four years on the news CEO Steve Ballmer planned to retire. Read the full article at http://www.marketwatch.com/story/microsoft-is-mondays-stock-to-watch-2013-08-24?siteid=yhoof2.
FinancialNewsMedia.com is leading provider of third party publishing &
|SOURCE FN Media Group LLC|
Copyright©2012 PR Newswire.
All rights reserved